Aug 05, 2024
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 01, 2024
Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update
Jul 29, 2024
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia
Jul 25, 2024
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024
Jul 05, 2024
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 14, 2024
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
Jun 06, 2024
Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC
Jun 05, 2024
Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference
Jun 03, 2024
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 15, 2024
Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors
May 09, 2024
Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference
May 08, 2024
Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
May 03, 2024
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 10, 2024
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
Apr 05, 2024
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 05, 2024
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 28, 2024
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
Mar 26, 2024
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
Mar 01, 2024
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 27, 2024
Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update